NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02569242,Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer,https://clinicaltrials.gov/study/NCT02569242,,COMPLETED,The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.,YES,Esophageal Cancer,DRUG: Nivolumab|DRUG: Docetaxel/Paclitaxel,"Overall Survival, (""Date of death from any cause"" - ""Date of randomization"" + 1) / 30.4375. For subjects lost to follow-up and subjects who are alive at the time of data cutoff date, data will be censored at the time the subject was last confirmed to be alive.","Progression-free Survival, Please refer to the protocol, overall response and best overall response will be determined solely by imaging assessment according to the RECIST Guideline Version 1.1, and will not take into account any clinical/symptomatic progression. Evaluable imaging data will be overall response without an overall response of ""Not Evaluable (NE)."", (""Earlier date on which either the overall response was assessed as PD or the subject died of any cause"" - ""Date of randomization"" + 1) / 30.4375.|Duration of Response, Please refer to the protocol, overall response and best overall response will be determined solely by imaging assessment according to the RECIST Guideline Version 1.1, and will not take into account any clinical/symptomatic progression. Evaluable imaging data will be overall response without an overall response of ""Not Evaluable (NE)."", (""Earlier date on which either the overall response was assessed as PD for the first time after confirmed response or the subject died of any cause"" - ""Date of first assessment of confirmed CR or PR"" + 1) / 30.4375.",,Ono Pharmaceutical Co. Ltd,Bristol-Myers Squibb,ALL,"ADULT, OLDER_ADULT",PHASE3,419,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,ONO-4538-24/CA209-473,2015-12-14,2020-10-23,2020-10-23,2015-10-06,2022-01-14,2022-07-06,"Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234, United States|Georgetown University Med Ctr, Washington, District of Columbia, 20007, United States|Orlando Health, Inc, Orlando, Florida, 32806, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Duke Cancer Institute, Durham, North Carolina, 27710, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, 37232, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Odense University Hospital, Odense C, 5000, Denmark|RWTH Aachen University, Aachen, 52057, Germany|Charite Campus Virchow Klinikum, Berlin, D-13353, Germany|University Hospital Heidelberg, Heidelberg, 69120, Germany|Universitatsklinikum Jena, Innere Medizin II, Jena, 07747, Germany|MVZ Mitte, Leipzig, 04103, Germany|University Of Mainz Medical Center, Mainz, 55131, Germany|Klinikum reechts der Isar, Technical University Munchen, Munich, 81675, Germany|HPG23, Bergamo, 24127, Italy|Fondazione Irccs Istituto Nazionale Tumori, Milan, 20133, Italy|Irccs Istituto Oncologico Veneto Iov, Padova, 35128, Italy|Aichi Clinical Site, Nagoya, Aichi, 464-8681, Japan|Aichi Clinical Site, Nagoya, Aichi, 466-8560, Japan|Aomori Clinical Site, Hirosaki, Aomori, 036-8563, Japan|Chiba Clinical Site, Kashiwa, Chiba, 277-8577, Japan|Ehime Clinical Site, Matsuyama, Ehime, 791-0288, Japan|Hokkaido Clinical Site, Sapporo, Hokkaido, 003-0027, Japan|Hokkaido Clinical Site, Sapporo, Hokkaido, 060-8648, Japan|Hyogo Clinical Site, Akashi, Hyogo, 673-0021, Japan|Hyogo Clinical Site, Kobe, Hyogo, 650-0047, Japan|Kanagawa Clinical Site, Isehara, Kanagawa, 259-1193, Japan|Kanagawa Clinical Site, Kawasaki, Kanagawa, 216-0015, Japan|Kanagawa Clinical Site, Yokohama, Kanagawa, 236-0004, Japan|Kanagawa Clinical Site, Yokohama, Kanagawa, 241-8515, Japan|Mie Clinical Site, Tsu, Mie, 514-8507, Japan|Miyagi Clinical Site, Sendai, Miyagi, 980-8574, Japan|Nagano Clinical Site, Saku, Nagano, 385-0051, Japan|Niigata Clinical Site, Nigatake, Niigata, 951-8520, Japan|Osaka Clinical Site, Osakasayama, Osaka, 589-8511, Japan|Osaka Clinical Site, Suita, Osaka, 565-0871, Japan|Osaka Clinical Site, Takatsuki, Osaka, 569-0801, Japan|Saitama Clinical Site, Hidaka, Saitama, 350-1298, Japan|Saitama Clinical Site, Kita-Adachi County, Saitama, 362-0806, Japan|Shizuoka Clinical Site, Suntou County, Shizuoka, 411-8777, Japan|Tochigi Clinical Site, Shimotsuke, Tochigi, 329-0431, Japan|Tokyo Clinical Site, Bunkyo-ku, Tokyo, 113-0021, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, 104-0045, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, 104-8560, Japan|Tokyo Clinical Site, Koto-ku, Tokyo, 135-8550, Japan|Tokyo Clinical Site, Meguro-ku, Tokyo, 152-8902, Japan|Tokyo Clinical Site, Minato-ku, Tokyo, 105-8470, Japan|Tokyo Clinical Site, Shinagawa-ku, Tokyo, 142-8666, Japan|Tokyo Clinical Site, Shinjuku-ku, Tokyo, 160-8582, Japan|Tokyo Clinical Site, Shinjuku-ku, Tokyo, 162-8666, Japan|Akita Clinical Site, Akita, 010-8543, Japan|Chiba Clinical Site, Chiba, 260-0801, Japan|Chiba Clinical Site, Chiba, 260-8677, Japan|Fukuoka Clinical Site, Fukuoka, 812-8582, Japan|Fukushima Clinical Site, Fukushima, 960-1295, Japan|Hiroshima Clinical Site, Hiroshima, 734-8551, Japan|Kagoshima Clinical Site, Kagoshima, 890-8520, Japan|Kumamoto Clinical Site, Kumamoto, 860-8556, Japan|Kyoto Clinical Site, Kyoto, 602-8566, Japan|Kyoto Clinical Site, Kyoto, 606-8507, Japan|Niigata Clinical Site, Niigata, 951-8566, Japan|Osaka Clinical Site, Osaka, 537-8511, Japan|Shizuoka Clinical Site, Shizuoka, 420-8527, Japan|Busan Clinical Site, Busan, 49241, Korea, Republic of|Daegu Clinical Site, Daegu, 41404, Korea, Republic of|Daegu Clinical Site, Daegu, 41931, Korea, Republic of|Daejeon Clinical Site, Daejeon, 35015, Korea, Republic of|Gyeonggi-do Clinical Site, Gyeonggi-do, 13620, Korea, Republic of|Hwasun-Gun Clinical Site, Hwasun-Gun, 58128, Korea, Republic of|Seoul Clinical Site, Seoul, 03080, Korea, Republic of|Seoul Clinical Site, Seoul, 03722, Korea, Republic of|Seoul Clinical Site, Seoul, 05505, Korea, Republic of|Seoul Clinical Site, Seoul, 06351, Korea, Republic of|Seoul Clinical Site, Seoul, 06591, Korea, Republic of|Ulsan Clinical Site, Ulsan, 44033, Korea, Republic of|Changhua Clinical Site, Changhua, 500, Taiwan|Chiayi Clinical Site, Chiayi, 61363, Taiwan|Kaohsiung Clinical Site, Kaohsiung, 807, Taiwan|Kaohsiung Clinical Site, Kaohsiung, 82445, Taiwan|Kaohsiung Clinical Site, Kaohsiung, 83301, Taiwan|Keelung Clinical Site, Keelung, 20445, Taiwan|Taichung Clinical Site, Taichung, 40447, Taiwan|Tainan Clinical Site, Tainan, 704, Taiwan|Taipei Clinical Site, Taipei, 10048, Taiwan|Taipei Clinical Site, Taipei, 11217, Taiwan|Taoyuan Clinical Site, Taoyuan, 333, Taiwan|Velindre Cancer Centre, Cardiff, Cardiganshire, CF142TL, United Kingdom|The Beatson West Of Scotland Cancer Centre, Glasgow, Lanarkshire, G12 0YN, United Kingdom","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/42/NCT02569242/Prot_SAP_000.pdf"
